The role of TNF in cardiovascular disease

被引:134
作者
Ferrari, R [1 ]
机构
[1] Univ Ferrara, Ctr Fisiopatol Cardiovasc, Fdn S Maugeri, I-25064 Brescia, Italy
关键词
TNF-alpha; heart failure; cytokines;
D O I
10.1006/phrs.1998.0463
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is increasing evidence that cytokines in general and tumour necrosis factor (TNF) in particular play an important role in cardiovascular disease. This is not surprising since TNF modulates both cardiac contractility and peripheral resistance, the two most important haemodynamic determinants of cardiac function. Thus, increased levels of TNF or of its soluble receptors have been implicated in the pathophysiology of ischaemia-reperfusion injury, myocarditis, cardiac allograft and, more recently, also in the progression of congestive heart failure. In this later condition, TNF could be responsible for further ventricular remodelling; down-regulation of myocardial contractility; increased rate of apoptosis of the endothelial cell and of the myocytes, alteration of the expression and function of the enzymes regulating nitric oxide production and, of course, the induction of cachexia resulting in further peripheral muscle dysfunction. The hypothesis that TNF may be involved in the progression of CHF may be of clinical relevance as anti-TNF strategies are considered for therapeutical strategies. The purposes of this article are: (1) to define the physiological aspects of TNF; (2) to outline the specific function of TNF within the heart; (3) to consider the role of TNF in CHF; and (4) to speculate on possible anti-TNF treatment. (C) 1999 Academic Press.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 90 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] ABRAHAM E, 1995, 2 ANN AUT M DEAUV FR
  • [3] STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS
    ADERKA, D
    ENGELMANN, H
    MAOR, Y
    BRAKEBUSCH, C
    WALLACH, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 323 - 329
  • [4] Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93
  • [5] AGNOLETTI L, 1997, 4 C NAZ SOC IT RIC C, P6
  • [6] Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure
    Anker, SD
    Egerer, KR
    Volk, HD
    Kox, WJ
    PooleWilson, PA
    Coats, AJS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (10) : 1426 - &
  • [7] ARBUSTINI E, 1991, AM J PATHOL, V139, P709
  • [8] Benigni F, 1996, AM J PATHOL, V149, P1847
  • [9] PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN
    BEUTLER, B
    MILSARK, IW
    CERAMI, AC
    [J]. SCIENCE, 1985, 229 (4716) : 869 - 871
  • [10] TUMOR NECROSIS, CACHEXIA, SHOCK, AND INFLAMMATION - A COMMON MEDIATOR
    BEUTLER, B
    CERAMI, A
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1988, 57 : 505 - 518